NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
2.950
-0.080 (-2.64%)
At close: Apr 28, 2026, 4:00 PM EDT
3.030
+0.080 (2.71%)
Pre-market: Apr 29, 2026, 4:13 AM EDT
NRx Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 1.23 | - | - | - | - | |
| Cost of Revenue | 0.51 | - | - | - | - | |
| Gross Profit | 0.72 | - | - | - | - | |
| Selling, General & Admin | 13.06 | 13.5 | 14.22 | 27.31 | 74.94 | |
| Research & Development | 3.78 | 6.2 | 13.37 | 17.03 | 20.26 | |
| Other Operating Expenses | - | - | - | - | -0.77 | |
| Operating Expenses | 16.91 | 19.7 | 27.59 | 44.34 | 94.43 | |
| Operating Income | -16.19 | -19.7 | -27.59 | -44.34 | -94.43 | |
| Interest Expense | -0.67 | -0.23 | -0.12 | - | -0.02 | |
| Interest & Investment Income | 0.01 | 0.04 | 0.49 | 0.25 | - | |
| Other Non Operating Income (Expenses) | -7.77 | -3.78 | 0.02 | 0.26 | 1.69 | |
| EBT Excluding Unusual Items | -24.61 | -23.67 | -27.19 | -43.83 | -92.76 | |
| Gain (Loss) on Sale of Investments | -0.04 | - | - | - | - | |
| Other Unusual Items | -3.98 | -1.45 | -2.96 | 4.08 | -0.31 | |
| Pretax Income | -28.62 | -25.13 | -30.15 | -39.75 | -93.06 | |
| Net Income | -28.62 | -25.13 | -30.15 | -39.75 | -93.06 | |
| Preferred Dividends & Other Adjustments | - | - | 0.01 | - | - | |
| Net Income to Common | -28.62 | -25.13 | -30.16 | -39.75 | -93.06 | |
| Shares Outstanding (Basic) | 21 | 11 | 8 | 7 | 5 | |
| Shares Outstanding (Diluted) | 21 | 11 | 8 | 7 | 5 | |
| Shares Change (YoY) | 101.06% | 40.50% | 15.20% | 40.17% | 36.90% | |
| EPS (Basic) | -1.34 | -2.36 | -3.98 | -6.04 | -19.84 | |
| EPS (Diluted) | -1.34 | -2.36 | -3.98 | -6.04 | -74.40 | |
| Free Cash Flow | -14.11 | -10.64 | -21.66 | -39.77 | -37.71 | |
| Free Cash Flow Per Share | -0.66 | -1.00 | -2.86 | -6.05 | -8.04 | |
| Gross Margin | 58.78% | - | - | - | - | |
| Operating Margin | -1321.47% | - | - | - | - | |
| Profit Margin | -2336.49% | - | - | - | - | |
| Free Cash Flow Margin | -1152.00% | - | - | - | - | |
| EBITDA | -16.12 | -19.7 | -27.58 | -44.33 | -94.43 | |
| D&A For EBITDA | 0.07 | 0.01 | 0.01 | 0 | 0 | |
| EBIT | -16.19 | -19.7 | -27.59 | -44.34 | -94.43 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.